Prior Authorization Form

(*Required)



Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information	Prescriber Information
Patient Name:	Prescriber Name:
Health Plan Name:	Prescriber Address:
Patient Insurance Id:	
Patient Date of Birth:	Prescriber Phone: ()
Patient Phone:	Prescriber Fax: ()
	Prescriber Specialty:
	Prescriber DEA:
	Prescriber NPI:
Medica	tion & Medical Information
Requested Drug(s) & Strength(s):	[] Xenpozyme 20 mg intravenous solution
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	
	Overtionnains
	Questionnaire
	the provider, certify and attest that the information provided is complete ny information to RxAdvance that RxAdvance determines is reasonably t apply)
[] Yes	
[] No	
Q2: Is the member currently treated with this medical	tion? (Check only one that apply)
[] Yes (please list start date of therapy (month/d	ay/year)

Prior Authorization Form



[] No		
Q3: What is the member's diagnosis? (Check only one that apply)		
[] Acid sphingomyelinase deficiency (ASMD)		
[] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)		
Q4: Does the member have a documentation of positive clinical response to therapy (e.g., do size, increase in platelet count, improved lung function)? (Check only one that apply)	ecrease in spleen size, decrease in liver	
[] Yes (please provide documentation(s) supporting the positive response of the therap(*Required)	py)	
[] No (please provide medical justification for continuation of therapy)(*Required)		
Q5: What is the member's diagnosis? (Check only one that apply)		
[] Acid sphingomyelinase deficiency (ASMD)		
[] Other (please specify the member's diagnosis and provide clinical rationale for the re(*Required)	equest)	
Q6: Does the member have molecular genetic testing confirming biallelic pathogenic variant phophodiesterase-1) gene? (Check only one that apply)	s in the SMPD1 (sphingomyelin	
[] Yes		
[] No		
Q7: Does the member have a confirmed residual acid sphingomyelinase activity that is less t blood lymphocytes or cultured skin fibroblasts)? (Check only one that apply)	han 10% of controls (in peripheral	
[] Yes		
[] No (please provide clinical rationale for the request)(*Required)		
Q8: Does the member have non-central nervous system manifestations of ASMD? (Check on	lly one that apply)	
[] Yes		
[] No (please provide clinical rationale for the request)(*Required)		
$\ensuremath{Q9}\xspace$ Is the requested medication prescribed by or in consultation with a metabolic disease spectral apply)	pecialist or geneticist? (Check only one	
[] Yes (please provide prescriber specialty)	(*Required)	
[] No (please provide clinical rationale for the request)(*Required)		
<u>Attestation:</u> I attest the information provided is true and accurate to the best of my knowledge. I under Medical Group or its designated representatives may perform a routine audit and request the medical accuracy of the information reported on this form.		
Signature of Prescriber or Authorized Representative:	Date:	

Prior Authorization Form

